A. U2OS cells were synchronized by a double thymidine block as described in the legend to Fig. 1 , or left asynchronous. Four hours before release from the block, all three sets of cells (S-phase, non-released and asynchronous) were treated with 10μM Nutlin-3a (and the DMSO solvent alone as a control). After the release, the previous concentrations of Nutlin was maintained. The cells were harvested 4 h after the release from the thymidine block. Immunoblot analysis was performed to detect p53 and its target gene product p21/CDKN1A, as well as β-actin as a loading control. Samples were processed in duplicate to ensure the reproducibility of the detection levels.
B.
Upon treatment as in A and RNA deep sequencing analysis, genes displaying an induction of greater than 2-fold and a p-value <0.05 in thymidine-blocked and subsequently released cells (Suppl . Table S1 ) were included in the analysis (left panel). Most of these genes were induced by p53 to a similar degree when the cells had not been released to enter S-phase (right panel). The genes were sorted according to their p-value identified in arrested, non-released cells. As a result, all genes found to be inducible during S phase were also induced in arrested cells.
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Suppl. Mdm2 when comparing the 3h incubation with the 14 h incubation (Blots as in Fig. 2A but including the 3h incubation).
B.
Nutlin treatment decreases DNA synthesis, but not completely. U2OS cells were treated with Nutlin for the indicated periods of time, followed by incubation with the nucleoside analogue EdU and staining of newly synthesized DNA. The proportion of DNA-synthesizing cells was determined at each time point.
C.
Nutlin treatment increases fork progression, as in Fig. 2 , B-D. U2OS cells were treated with 8 μM Nutlin for 14h, followed by DNA-labeling with 25μM CldU for 20 min, and then 250μM IdU for 2 h
D.
Quantification of fiber lengths from two independent experiments, as in Fig.2D .
E.
Three hours of Nutlin treatment do not suffice to increase replication fork progression. U2OS cells were treated with 8μM Nutlin for 3h, followed by incubation with CldU (25μM, 20mins) and IdU (250μM, 2h).
F.
The fork rate was not affected by Nutlin treatment for 3 hours.
G.
Increased fork rate upon 14 h Nutlin treatment is still visible by a short (i.e. 20 min) labeling protocol. U2OS cells treated with 8μM Nutlin for 14 hours were subjected to short pulses of CldU and IdU (both 25μM, 20 mins). Gemcitabine was added to the IdU label as indicated.
H.
Immunostaining of CldU (red) and IdU (green) was performed to visualize labeled replication tracks.
I.
Nutlin treatment significantly increased fork progression during short labeling times, too, in the presence or absence of gemcitabine.
Suppl. 
A.
Abolishing origin firing by Cdc7 inhibition does not affect Nutlin-driven fork progression. Fiber assays were carried out with U2OS cells treated with 8μM
Nutlin for 14 hours, followed by labeling with CldU (25μM, 20 mins) and IdU (25μM, 2h). A Cdc7 inhibitior, Cdc7i, 5μM PHA-767491, was added to avoid replication origin firing (Montagnoli et al., 2008) during the IdU label.
B.
As revealed by box plot analysis of the obtained track lengths, Nutlin treatment increased fork progression even in the presence of the Cdc7 inhibitor. Note that the Cdc7 inhibitor alone also increased for progression, in parallel to its ability to enhance p53 levels (cf. Panel C). 
C.
D.
Counterstaining of DNA fibers carrying labeled tracks. After incubating U2OS cells with the labels CldU and IdU, we performed fiber assays as in Fig. 2B -D. Before mounting the fibers, we stained the (denatured) DNA with a third primary antibody, directed against single stranded DNA, followed by a fluorescently labeled (Alexa647) secondary antibody. This made the fibers visible in far red (presented in blue in the composite image) and showed that the labeled tracks were part of a longer DNA fiber.
E.
Scheme depicting two different scenarios that could explain a shortened 2 nd label track. When compared to an unperturbed replication fork (1 top), slower DNA fork progression would lead to a shortened fiber (2 middle). However, premature fork stalling within the second labeling period could also lead to shortened fibers, even if the speed of replication forks remains the same (3 bottom).
F.
Additional images to document fork processivity and document the feasibility of multiple changes of label, as described in the legend to Fig To replicate the assays shown in Fig. 3 , B-D, U2OS cells were transfected with siRNA to knock down p53, or with control siRNA. Newly synthesized DNA was labeled by 25μM CldU for 20 min and then 250μM IdU supplemented with
Gemcitabine for 2 h and controls for 1h, followed by fiber assays.
B.
Immunostained replication tracks of CldU (red) and IdU (green).
C.
The lengths of IdU-labeled tracks were used to assess replication fork progression upon p53 knockdown or control siRNA transfection. In the presence or absence of gemcitabine, p53 depletion yielded reduced fork rates.
D.
P53 depletion and fiber assays were carried out as in Panel A, but shorter labeling pulses were applied, i.e. incubations for 20 minutes with CldU and then IdU (both 25μM). Gemcitabine was added to the second label (IdU) only.
E.
Immunostaining revealed short red (CldU) and green (IdU) tracks.
F.
The fork rates, as determined by the lengths of the IdU tracks, are displayed as boxplots. Despite the shorter labeling time (and thus reduced likelihood of fork collapse during it), p53-dependent differences were still observed.
G.
Cell cycle 
B.
Immunostaining of CldU (red) and IdU (green) visualized the continuation of replication after the HU block.
C.
The rate at which forks continue to replicate after the HU block was determined by quantification of red-only (stalled) and red-green (continuing) structures. No difference was observed between the four samples.
D.
Lack of fork regression upon HU treatment. The length of the first label track (before HU block) was determined to reveal any possible fork regression.
Regardless of HU treatment or p53 depletion, the length of the first, CldUlabeled track was unaffected. Hence, p53 depletion does not give rise to degradation of stalled replication forks, unlike the depletion of BRCA1 (Chaudhuri et al., 2016 ).
E.
Cells were treated as in Panel A. Instead of one short pulse of CldU prior to HU treatment, the cells were subjected to three short (20 mins) pulses of CldU, IdU, and CldU (all 25μM) before a 2h block with 2mM HU and a subsequent 1h IdU labeling (25μM). Controls were labeled with IdU for 1h directly after the last CldU label.
F.
Immunostaining revealed the expected pattern of red (CldU) and green (IdU) labels to indicate that replication continued after the HU block.
G.
The rate of fork restart after the HU label was assessed by quantifying all structures with three short labels only (no restart) and the ones with three short and one long green label (restart). No reduction in the restart rate was seen upon p53 depletion.
H.
Lack of fork regression regardless of p53 proficiency. After treatment as in Panel N, the ratio of the 3 rd label (20 min CldU) and the 2 nd label (20 min IdU) was determined. As expected, this ratio was close to 1, suggesting that the 3 rd track was not subject to fork regression during the HU block. This ratio was not diminished as a result of p53 knockdown.
I.
Replication progression was assessed by measuring the length of the last IdU label (1h), confirming that the preceding HU block impairs the progression of DNA replication, and that p53 depletion further exacerbates replicative stress in this context.
J.
Depletion of Mdm2 from HCT116 cells with a targeted deletion of p53. The cells were transfected with siRNA to Mdm2 or control siRNA, followed by immunoblot analysis. The cells were then subjected to fiber assays, as outlined in Fig. 3H -J.
K.
RNA levels corresponding to the pathways responding to replicative stress.
Upon siRNA-mediated depletion of Mdm2 from p53-deficient HCT116 cells, RNA samples were subjected to deep sequencing analysis. No significant differences in the mRNA levels corresponding to the indicated genes were observed. The data were derived from our previous work (Wienken et al., 2016) . OHT to remove the floxed p53 gene, or control-treated, for 48 hours. This was followed by incubation with normal media for 24 hours, and subsequent incubation with 25μM CldU for 20 min, followed by 250μM IdU for 2 h. During the second labeling period, 400nM Gemcitabine was added as indicated.
B.
MEFs with two floxed p53 alleles, treated with 4-OHT and/or gemcitabine, were compared as to their DNA replication, as in Fig. 4F . The removal of p53 by 4-OHT decreased fork progression.
C.
Fiber lengths are displayed comparing 4-OHT treated cells with two, one or no floxed p53-allele, treated with gemcitabine, as in Fig. 4I . Even one floxed p53 allele compromised DNA replication, and two floxed alleles did so to a greater extent.
D.
The cell cycle distribution of MEFs treated with 4-OHT was determined by propidium iodide and flow cytometry, and summarized in Panel E. No increase in S phase fractions was observed in p53-deficient MEFs.
F.
The deletion of mdm2 on a p53-/-MEF background does not detectably alter the mRNA levels corresponding to genes that are relevant to replicative stress.
The expression levels were determined by RNA sequencing analysis as in Suppl. Fig. 5K , based on the data from (Wienken et al., 2016) . P53 does not detectably affect mitochondrial ROS levels in thymocytes. Flow cytometry to detect ROS was carried out as in Suppl. Fig. 4I .
B.
Replicates from Fig. 5 , B-E, in independent experiments using thymocytes from different mice. Thymocytes were isolated from mice with differernt p53 status (wild type, null, or heterozygous). Immediately after isolation, replicating DNA was labeled using 25 μM CldU for 20 min, followed by 25 μM IdU for 2 h. Fiber 
E.
Short pulses of CldU and IdU (25μM, 20 mins each) were used to confirm enhanced replicative stress in p53-deficient thymocytes. Gemcitabine was added together with the IdU label as indicated.
F.
Immunostaining was performed to detect the (short) labeled tracks of CldU (red) and IdU (green).
G.
Despite the short 2 nd pulse and concomitant decreased likelihood of fork stalling, reduced fork progression was observed when evaluating the length of the IdU-labeled tracks in gemcitabine-treated cells.
H.
The cell cycle distribution of the thymocytes was determined by propidium 
3E
One out of three data sets is shown in each case (DMSO treatment, Suppl. Table S2 vs.
Nutlin treatment, Suppl. Table S3 , of U2OS cells). The following numbers were obtained for each track, shown in separate Excel sheets.
Fork stalling
Raw Image J data from the Cell counter Plugin were used to calculate how many labels have been incorporated. Percentages were calculated dividing the number of tracks with less than all seven labels by the total number of tracks.
Track length
Raw ImageJ data from Segmented line tool. Calculation of track length in pixel to micrometers by a conversion factor of 3 (determined by measuring a scale bar under the same microscope settings). This page additionally provides information on the average length of each individual label analysed for this sample.
Fork rate
Raw ImageJ data from Segmented line tool. Calculation of fork progression in two steps.
First, the pixel to micrometer conversion is carried out as described above. Next, the length in micrometers is converted to kilobases by a conversion factor of 2.59, and a rate is calculated by dividing the number of bases by the labeling time of the stretch analysed. The average speed of each individual label is also assessed. For progression analysis, the length of labels 2-5 of fibres that contained at least 5 labels was used. For this, the length of the first label was deducted from the length of labels 1-5 measured and subjected to the same conversion to a progression rate as described above.
Individual Label Length
This table reports the length of individual labeled tracks of all analysed fibres.
Individual Label Speed
This table provides the fork speed corresponding to all individual labeled tracks.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Cell culture, siRNA transfections and treatment U2OS (Osteosarcoma, p53 wild type), were maintained in Dulbecco's modified Eagle's medium (DMEM). Cell culture media were supplemented with 10% fetal calf serum (FCS) and antibiotics. Cells were maintained at 37°C in a humidified atmosphere with 5% CO 2 . A Nutlin-3a (Sigma, N6287) stock solution was prepared in DMSO, diluted in pre-warmed medium and added to the cells for the indicated periods of time. Aqueous gemcitabine (Eli Lilly) and hydroxyurea (Sigma, H8627) stock solutions were used.
For siRNA knockdown, U2OS or HCT116p53-/-cells were reverse transfected with 10nM siRNA to p53 (s605, s607 Ambion), to Mdm2 (Ambion; custom made, AAGCCAUUGCUUUUGAAGUUAtt (sense), UAACUUCAAAAGCAAUGGCUUtt (antisense)) and a negative control siRNA, using Lipofectamine 2000. Medium was changed after 24 hours, followed by further incubation for 24 hours.
Isolation of fibroblasts and thymocytes from mice
Mouse embryonic fibroblasts (MEFs) were isolated from p53 loxP mice (Jonkers et al., 2001 ) (B6.129P2-Trp53tm1Brn/J, Jackson Laboratories) at E13.5. Littermates were used to prepare MEFs from a C57Bl6N/129SV background (50%-50%, N2 Backcross).
MEFs from p53-/-and from p53-/-;mdm2-/-mice with a mostly C57BL/6 background were obtained from Y. Zhang, University of North Carolina, as previously (Itahana et al., 2007; Wienken et al., 2016) . MEF cultures were maintained in DMEM supplemented with 10% FCS, L-glutamine, sodium pyruvate, and antibiotics.
Thymocytes were isolated from four weeks old Trp53tm1Tyj mice (Jackson Laboratories), carrying a deletion of the p53-encoding gene (Jacks et al., 1994 
Cell synchronization
U2OS cells were incubated with thymidine at 2 mM in DMEM/10% FCS for 16 h, then washed and incubated in DMEM/10% FCS for 8 h, and then again incubated with 2 mM thymidine for 16 h (double-thymidine block). For release, thymidine was removed by washing and incubation with DMEM/10% FCS.
Immunoblot analysis
Cells were harvested in protein lysis buffer (20 mM TRIS-HCl pH 7.5, 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1 mM beta-glycerophosphate, 2 M urea, protease inhibitor cocktail, Roche). The samples were briefly sonicated to disrupt DNA-protein complexes.
Total protein concentration was measured using a Pierce BCA protein assay kit (Thermo Scientific Fisher). After boiling the samples in Laemmli buffer at 95°C for 5 min, equal amounts of protein samples were separated by SDS-PAGE, transferred onto nitrocellulose, and visualized with the following antibodies: γH2AX (S139) (9718, Cell
Signalling), β-Actin (ab6276-100, Abcam), p21 (2947, Cell Signalling; F5 sc-6246, Santa Cruz), Mdm2 (OP 46, Calbiochem), p53 (DO-1 sc-126, Santa Cruz; CM5 VP-P956, Vector Laboratories), HSC70 (sc-7298, Santa Cruz).
Flow cytometry
For cell cycle analysis, U2OS cells were synchronized as described above. After fixation in ethanol, cells were washed with 0.05% Triton-X in PBS. Subsequently, the cells were resuspended in 1 mg/ml RNAse A solution in PBS and incubated for 30 min at 37°C, and then with propidium iodide (final concentration: 30 µg/ml). Flow cytometry was performed using the Guava PCA-96 Base System (Millipore), and the percentage of cells in each phase of the cell cycle was determined using the Guava Express Pro software.
For detection of mitochondrial reactive oxygen species, living cells were incubated with 5 M MitoSOX™ Red Mitochondrial Superoxide Indicator (Invitrogen) in FACS binding buffer (Hanks Balanced Solution + 5mM CaCl2, 5mM MgCl2, 1% BSA) at 37°C and 5%
CO 2 for 40 minutes. After washing with PBS (37°C) twice, the cells were detached with 0.5% trysin/EDTA, followed by flow cytometry.
RNA extraction, reverse transcription, and real time quantitative PCR
Total RNA was extracted from cells using TRIzol® (Invitrogen). mRNA was reversetranscribed using oligo-dT and random hexameric primers, followed by qRT-PCR analysis using SYBR Green (Invitrogen). Gene expression levels were normalized to the mRNA encoding 36B4, and the analysis was conducted using the ΔΔCt method. qRT-PCR primer sets were chosen as follows: 
Primer sequences for gene expression studies in human cells
RNA sequencing
For RNA-sequencing, the quality of total RNA was determined using the Bioanalyzer (Kim et al., 2013) . Read counts for each sample and each gene were aggregated using a htseqcount . DESeq2 (version 1.10.1) was used for measuring differential expression (Love et al., 2014) . RNA library preparation and sequencing was done by the Transcriptome Analysis Laboratory (TAL, Göttingen).
Fiber assays
DNA fiber assays to analyze replication fork progression and origin firing were essentially carried out as described previously (Kopper et al., 2013) . For two-label assays, the cells were pulse-labeled with 5-chloro-2′-deoxyuridine (CldU) for 20 min, followed by 5-iodo-2′-deoxyuridine (IdU; both from Sigma-Aldrich) for 20 min, 1 or 2 h, accompanied by treatment with gemcitabine or inhibitors as indicated. For multiple label assays, cells were pulse labeled with CldU for 1 hour, followed by alternate labels of IdU and CldU.
Gemcitabine was added to the cells as indicated, along with the second label (IdU). The concentrations of gemcitabine had to be adjusted since different cell types (U2OS, MEFs, thymocytes) responded to gemcitabine to different extents. There are multiple reasons for different pharmacokinetics of this drug on the cellular level, including transport, metabolism and the levels of ribonucleotide reductase, one of the target structures of gemcitabine (Mini et al., 2006) . This made it necessary to find a concentration for each cell type that allowed us to observe p53-dependent changes in both directions.
DNA fibers were spread on glass slides as described (Kopper et al., 2013) . After acid treatment, CldU-and IdU-labeled tracts were detected by 1 h incubation at 37 °C with rat labeled tracks were measured in pixels by a person blinded as to the identity of the sample, and by using the Fiji software. The track lengths were then converted to micrometers and subsequently converted to kb using the conversion factor 1 μm = 2.59
kb. Only monodirectional replication structures (red-green) were quantified by using the Cell Counter Plug-in for Fiji (Kurt De Vos, University of Sheffield, Sheffield, United Kingdom). To determine P values, we employed Student's unpaired, 2-sided T-test.
High-Content Immunofluorescence Microscopy
Cells were grown in 96-well imaging plates (Becton Dickinson) for 24h and treated with 10μM Nutlin-3a for 6, 12, and 24 hours. For the last 2 hours, 5μM 5-ethynyl-2'-deoxyuridine (EdU) was added to the media. After fixation in 4% paraformaldehyde/PBS, cells were permeabilized with 0.5% Triton-X100/PBS. Actively replicating cells were detected by using the Click-iT EdU Alexa488 HCS assay kit (Life Technologies, C10351). Hoechst staining was performed to detect cell nuclei. Automated microscopy was performed by using a Pathway HT Cell Imaging System in conjunction with the AttoVision image acquisition software (Becton Dickinson) and a single cell based image analysis. Quantification of DNA replication was determined in quadruplicate by background-corrected EdU signal intensity.
Statistical testing
Statistical testing was performed using Graph Pad Prism 6. An 2-sided unpaired t test was calculated with an assumed significance for p-values ≤ 5%. The term "n.s." indicates that no significant difference was found.
